摘要
目的:对赛沃替尼与克唑替尼这2组方案治疗间质-上皮细胞转化因子(mesenchymal-epithelial transition factor,MET)突变的局部晚期或转移性非小细胞肺癌(non-small cell lung cancer,NSCLC)进行成本-效果分析,以期为医疗卫生决策提供参考.方法:基于临床试验数据,构建分区生存模型,从中国卫生体系角度出发,计算2组的总成本、质量调整生命年(quality adjusted life years,QALY)和增量成本-效果比(incremental cost-effectiveness ratio,ICER),年贴现率为 5％,并采用单因素敏感性分析和概率敏感性分析法来评估参数结果的稳定性.结果:赛沃替尼组所产生的总成本为442 232元,可获得0.931 QALYs;克唑替尼组则产生322 138元的总成本,可获得0.677 QALYs,得出赛沃替尼组对比克唑替尼组的ICER为472 799元/QALY,高于我国的意愿支付阈值(257 094元/QALY).结论:从中国医疗体系的角度出发,赛沃替尼对比克唑替尼治疗MET突变的局部晚期或转移性NSCLC不具有成本-效果性.
Abstract
OBJECTIVE To evaluate the cost-effectiveness of savolitinib group versus crizotinib group in first-line treatment of locally advanced or metastatic non-small-cell lung cancer(NSCLC)with mesenchymal-epithelial transition factor(MET)mutations to provide references for healthcare decision-making.METHODS Based upon the clinical trial data,a partitioned sur-vival model was constructed from the perspective of Chinese healthcare system.Total expense,quality-adjusted life-years(QALY)and incremental cost-effectiveness ratio(ICER)of two groups were calculated and annual discount rate was 5％.Single factor sensitivity analysis and probabilistic sensitivity analysis were performed for evaluating the stability of parametric results.RESULTS Total expense of savolitinib group was ¥442 232 and 0.931 QALYs was obtained.Total expense of crizotinib group was ¥322 138 and 0.677 QALYs was obtained.ICER of savolitinib group versus crizotinib group was ¥472 799/QALY.It exceeded the willingness-to-pay threshold of ¥257 094/QALY in China.CONCLUSION From the perspective of Chinese healthcare system,savolitinib is not cost-effectiveness as compared with crizotinib for locally advanced or metastatic NSCLC with MET mutations.
NETL
NSTL
万方数据